D. Planche Wilmer R. Totty difficile Disease H. Boone

46 SCIENTIFIC SESSIONS September 9-12 | C2-143 Susceptibility of Gram-Positive Wound Pathogens in Eastern Europe: A Multi-Year Update of the TEST Study

M. Hackel

1 , S. Bouchillon 1 , D. Hoban 1 , R. Badal 1 , J. Johnson 1 , S. Hawser 2 ; 1 IHMA, Inc., Schaumburg, IL, 2 IHMA Europe Sàrl, Epalinges, Switzerland. C2-144 Monitoring of Tigecycline In Vitro Activity in Nosocomial Pneumonia Isolates from North American Intensive Care Units: TEST Data 2006-2011

D. Hoban, M. Hackel, R. Badal, S. Bouchillon, B. Johnson; IHMA, Inc., Schaumburg, IL.

C2-145 Activity of Ceftaroline CPT and Comparator Agents Tested against Contemporary 2010 Pathogens Commonly Associated with Respiratory Tract Infections RTI in Asia-Pacific APAC Countries and South Africa SAF D. J. Biedenbach, R. K. Flamm, D. J. Farrell, H. S. Sader, R. N. Jones; JMI Lab., N Liberty, IA. C2-146 Antimicrobial Activity of Ceftaroline Tested against Bacteria Collected from Patients with Community-Acquired Respiratory Tract Infections CARTI in the USA 2008-2011 R. N. Jones, R. K. Flamm, P. R. Rhomberg, H. S. Sader; JMI Lab., Inc., N Liberty, IA. C2-147 Extended-Spectrum ß-Lactamase ESBL In Vitro Activity in Urinary Tract Infections: European TEST Program Results, 2004-2011

S. Bouchillon, M. Hackel, B. Johnson, D. Hoban, J. Johnson; IHMA, Inc., Schaumburg, IL.

C2-148 Epidemiology and Antimicrobial Susceptibility of Pathogens Associated with Bacterial Empyema: TEST 2004-2011

S. Bouchillon, R. Badal, B. Johnson, M. Hackel, D. Hoban; IHMA, Inc., Schaumburg, IL.

C2-149 In Vitro Activity of Ceftazidime-Avibactam formerly CAZ104 against Gram-Negative Pathogens Isolated from Pa- tients in Canadian Hospitals in 2009-2011: CANWARD Surveil- lance Study P. Lagacé-Wiens, H. Adam, A. Denisuik, J. Karlowsky, A. Walkty, D. Ho- ban, G. G. Zhanel; Univ. of Manitoba, Winnipeg, Canada. C2-150 In Vitro Activity of Tigecycline and Comparators against Gram-Negatives in Africa-Middle East: TEST 2007-2012

M. Renteria

1 , S. Bouchillon 1 , B. Johnson 1 , M. Hackel 1 , N. Raghubir 2 ; 1 IHMA, Inc., Schaumburg, IL, 2 Pfizer, Inc., Dubai, United Arab Emirates. C2-151 Dynamics of Susceptibility to Tigecycline and to an Extended Panel of Antimicrobials of Gram-Positive and Gram-Negative Bacteria in Portugal 2005-2011 C. Silva-Costa, A. Friaes, M. D. Pinho, M. Ramirez, J. Melo-Cristino; Faculdade de Med. de Lisboa, Lisboa, Portugal. C2-152 Enterobacteriaceae in the UK and Ireland 2011: Susceptibility to Old and New Agents

R. Reynolds

1 , S. Mushtaq 2 , A. Kidney 3 , BSAC Working Party on Resistance Surveillance; 1 Southmead Hosp., Bristol, United Kingdom, 2 Hlth. Protec- tion Agency, London, United Kingdom, 3 Quotient Bioresearch, Microbiol., Fordham, United Kingdom. ---------------------------------------------------------------------------------- 011 D Poster Session Clostridium difficile Diagnostics Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-153 Evaluation of the Accuracy and Cost Effectiveness of Strate- gies of Testing for Clostridium difficile

J. N. Wainaina

1 , M. A. Beilke 1 , T. Wisniewski 2 , J. Winner 2 , P. Sohnle 1 ; 1 Clement J. Zablocki Med. Ctr., Med. Coll. of Wisconsin, Milwaukee, WI, 2 Clement J. Zablocki Med. Ctr., Milwaukee, WI. D-154 Does a Rapid Diagnosis of Clostridium difficile Infection CDI Impact on Quality of Patient’s Management?

F. Barbut

1,2 , C. Eckert 1,2 , L. Surgers 1 , V. Lalande 1 , for the GRCn°2 EPIDIFF; 1 Hosp. Saint-Antoine, Paris, France, 2 Univ. Pierre et Marie Curie, Paris, France. D-155 The Efficient Use of Laboratory Testing in Support of Clos- tridium difficile Infection, Diagnosis, and Prevention: Comparing Antigen, Nucleic Acid Amplification, and GDH: What is the Most Efficient Testing Algorithm?

M. J. Bankowski

1,2 , A. Hose 1 , A. LeClaire 1 , T. Goo 1 , T. Koyamatsu 1 , W. Kim 1 ; 1 Diagnostic Lab. Services The Queen’s Med. Ctr., Aiea, HI, 2 John A. Burns Sch. of Med., Honolulu, HI. D-156 Evaluation of a New Glutamatedehydrogenase Immuno Assay in a Two Step Algorithm for the Diagnosis of Clostridium difficile Infection

J. Van Broeck, E. R. Icyeza, M. Delmée; Univ. Catholique de Louvain, Brus- sels, Belgium.

D-157 Performances of a New Test to Detect GDH in Stool Samples

C. Eckert

1,2 , C. Rambaud 1,2 , V. Lalande 3,2 , F. Barbut 1,2 ; 1 Saint-Antoine Hosp., Paris, France, 2 UPMC Univ. Paris 06, GRC n°2, Epidiff, Paris, France, 3 Saint-Antoine Hosp., AP-HP, Paris, France. D-158 Development and Evaluation of a Double Multiplex Real- Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of

C. difficile from Stool Samples

A. Kilic 1,2 , M. J. Alam 2 , N. L. Tisdel 3 , D. N. Shah 2,3 , M. Yapar 1 , T. M. Lasco 3 , K. W. Garey 2,3 ; 1 Gulhane Military Med. Academy, Ankara, Turkey, 2 Univ. of Houston Coll. of Pharmacy, Houston, TX, 3 St Luke’s Episcopal Hosp., Houston, TX. D-159 Improvement in Patient Management through the Use of a Clostridium difficile PCR Real-Time Stand Alone Test in Acute Hospital Setting

E. Casari

1 , A. Ferrario 1 , C. De Luca 1 , M. Calabrò 1 , S. Allibardi 2 , M. Lagioia 1 ; 1 IRCCS Ist. Clinico Humanitas, Rozzano Milan, Italy, 2 Cepheid Europe, Milano, Italy. D-160 Clinical Validation of Clostidium difficile Infection CDI Diagnostics: Importance of Toxin Detection

T. D. Planche

1 , K. A. Davies 2 , P. Coen 3 , D. Crook 4 , N. Shetty 3 , M. Wrener 3 , M. H. Wilcox 2 ; 1 St. George’s, Univ. of London, London, United Kingdom, 2 Leeds Teaching Hosp. NHS Trust, Leeds, United Kingdom, 3 UCLH NHS Fndn. Trust, London, United Kingdom, 4 Oxford Radcliffe NHS Trust, Oxford, United Kingdom. 47 SUNDAY SCIENTIFIC SESSIONS Final Program D-161 PCR Assay to Detect Clostridium difficile tcdC Mutants is Valuable in Characterizing Hospital Epidemiology

A. Wilmer

1 , E. Lloyd-Smith 2 , V. Leung 2 , T. Wong 1 , G. Ritchie 3 , S. Cham- pagne 3 , M. Romney 3 ; 1 Univ. of British Columbia, Vancouver, Canada, 2 St. Paul’s Hosp., Vancouver, Canada, 3 St. Paul’s Hosp., Vancouver, Canada. D-162 Elevated Fecal Lactoferrin Levels Correlate with the Presence of Clostridium difficile Toxin

H. R. Totty

1 , J. H. Boone 1 , R. J. Carman 1 , T. M. Kerkering 2 , D. M. Lyerly 1 ; 1 Techlab, Inc., Blacksburg, VA, 2 Carilion Clinic, Roanoke, VA. D-163 Higher Lactoferrin, Increased WBC, Stool Toxin and 027 Infection are Associated with More Severe

C. difficile Disease

J. H. Boone

1 , C. McCoy 1 , J. DiPersio 2 , M. Tan 2 , S. Salstrom 2 , K. Wickham 1 , R. Carman 1 , D. Lyerly 1 ; 1 TechLab, Inc., Blacksburg, VA, 2 Summa Hlth. System, Akron, OH. ------------------------------------------------------------------------ 012 D Poster Session Diagnosis of Infections of Implantable Devices and Biofilms Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-164 A Novel, Direct Susceptibility Testing Method of Vascular Prosthetic Grafts by E-Tests L. Stecken 1 , A. San Miguel 1 , F. M’zali 2 , A. Quinart 1 , X. Berard 1 , F. Sztark 1 ; 1 Bordeaux Teaching Hosp., Bordeaux, France, 2 Univ. of Bordeaux, Bordeaux, France. D-165 Sonication of Cardiac Devices and their Components: Mi- crobiological and Pathogenetic Implication in Cardiac Device Infections

A. Oliva